KYMR insider trade: CEO option exercise and matching share sales

Rhea-AI Filing Summary

Kymera Therapeutics (KYMR) reported insider transactions by its Chief Executive Officer on 10/29/2025 under a Rule 10b5-1 trading plan dated September 6, 2024. The CEO exercised 30,000 stock options at an exercise price of $2.08 per share and acquired 30,000 shares, then sold 30,000 shares in three trades at weighted average prices of $59.7225, $61.0186, and $61.4576.

The filing notes these sales occurred in multiple transactions within disclosed price ranges. Following the transactions, the reporting person held 660,482 shares of common stock directly. The stock option reported was fully vested and exercisable, and 405,559 derivative securities were beneficially owned following the transactions.

Insights

Insider transactions analyst

Administrative Form 4: option exercise and planned sales.

The CEO of Kymera Therapeutics exercised 30,000 options at $2.08 and sold an equal number of shares on 10/29/2025. The trades were executed pursuant to a Rule 10b5-1 plan dated September 6, 2024, which pre-schedules transactions.

Weighted average sale prices were reported at $59.7225, $61.0186, and $61.4576, with detailed price ranges available upon request. Post-transaction holdings were 660,482 common shares directly and 405,559 derivative securities beneficially owned.

This is a routine insider filing. Actual market impact depends on trading volumes and context; no additional timing or proceeds uses are stated in the excerpt.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mainolfi Nello

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/29/2025		M(1)		30,000	A	$2.08	690,482	D
Common Stock	10/29/2025		S(1)		1,862	D	$59.7225(2)	688,620	D
Common Stock	10/29/2025		S(1)		24,511	D	$61.0186(3)	664,109	D
Common Stock	10/29/2025		S(1)		3,627	D	$61.4576(4)	660,482	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.08	10/29/2025		M(1)			30,000	(5)	11/13/2029	Common Stock	30,000	$0	405,559	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.35 to $60.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.37 to $61.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.37 to $61.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	10/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did KYMR's CEO report on Form 4?

On 10/29/2025, the CEO exercised 30,000 options at $2.08 and sold 30,000 shares at weighted average prices of $59.7225, $61.0186, and $61.4576.

Were the KYMR trades under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan dated September 6, 2024.

How many KYMR shares did the CEO hold after the transactions?

The reporting person held 660,482 shares of KYMR common stock directly after the reported transactions.

What were the price ranges for the KYMR share sales?

The filing notes multiple transactions within ranges of $59.35–$60.01, $60.37–$61.34, and $61.37–$61.82.

What is the status of the stock options reported by KYMR's CEO?

The 30,000 options exercised at $2.08 were fully vested and exercisable; 405,559 derivative securities were beneficially owned following the transactions.